[go: up one dir, main page]

NO20070979L - Anvendelse av N-aryldiazaspirasykliske forbindelser i behandling av avhengighet - Google Patents

Anvendelse av N-aryldiazaspirasykliske forbindelser i behandling av avhengighet

Info

Publication number
NO20070979L
NO20070979L NO20070979A NO20070979A NO20070979L NO 20070979 L NO20070979 L NO 20070979L NO 20070979 A NO20070979 A NO 20070979A NO 20070979 A NO20070979 A NO 20070979A NO 20070979 L NO20070979 L NO 20070979L
Authority
NO
Norway
Prior art keywords
compounds
effective
significant
treatment
effects
Prior art date
Application number
NO20070979A
Other languages
English (en)
Inventor
Balwinder Singh Bhatti
Jozef Klucik
Gregory J Gatto
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of NO20070979L publication Critical patent/NO20070979L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Forbindelser, preparater og metoder for behandling av medikamentavhengighet, nikotinavhengighet og/eller fedme er beskrevet. Forbindelsene er N-aryl-diazaspirocykliske forbindelser, brodannede analoger av N-heteroaryl-diazaspirocykliske forbindelser eller prodrug eller metabolitter av disse forbindelser. Arylgruppen kan være en fem- eller seks-leddet heterocyklisk ring (heteroaryl). Forbindelsene er effektive for hemning av dopamin-produksjon og/eller sekresjon og følgelig er effektive ved hemning av den fysiologiske "belønnings" prosess som er forbundet med inntak av nikotin- og/eller ulovlige medikamenter. Forbindelsene og preparatene kan administreres i effektive mengder til å hemme dopaminfrigjøring, uten å resultere i merkbart uheldige bivirkninger (f.eks. bivirkninger så som betydelig økninger i blodtrykk og hjertetakt, betydelige negative effekter på mage-tarmkanalen og betydelige effekter på skjelettmuskel).
NO20070979A 2004-08-20 2007-02-21 Anvendelse av N-aryldiazaspirasykliske forbindelser i behandling av avhengighet NO20070979L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60347904P 2004-08-20 2004-08-20
PCT/US2005/029371 WO2006023630A2 (en) 2004-08-20 2005-08-18 The use of n-aryl diazaspiracyclic compounds in the treatment of addiction

Publications (1)

Publication Number Publication Date
NO20070979L true NO20070979L (no) 2007-03-19

Family

ID=35447974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070979A NO20070979L (no) 2004-08-20 2007-02-21 Anvendelse av N-aryldiazaspirasykliske forbindelser i behandling av avhengighet

Country Status (16)

Country Link
US (1) US20060058328A1 (no)
EP (1) EP1784184A2 (no)
JP (1) JP2008510711A (no)
KR (1) KR20070043008A (no)
CN (1) CN101022801A (no)
AU (1) AU2005277410B2 (no)
BR (1) BRPI0514509A (no)
CA (1) CA2575461A1 (no)
IL (1) IL180929A0 (no)
MX (1) MX2007002045A (no)
NO (1) NO20070979L (no)
NZ (1) NZ552792A (no)
RU (1) RU2387647C9 (no)
UA (1) UA92327C2 (no)
WO (1) WO2006023630A2 (no)
ZA (1) ZA200701193B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
WO2004056363A2 (en) * 2002-12-20 2004-07-08 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
EP1998748B1 (en) 2006-03-16 2015-01-14 NicoNovum AB Improved snuff composition
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
US8575167B2 (en) 2007-02-06 2013-11-05 Takeda Pharmaceutical Company Limited Spiro compounds having stearoyl-CoA desaturase action
JP2011509933A (ja) * 2008-01-15 2011-03-31 ターガセプト，インコーポレイテッド ７−（３−ピリジニル）−１，７−ジアザスピロ［４．４］ノナンの調製およびエナンチオマー分離、ならびにそのラセミ体およびエナンチオマーの新規な塩形態
CN102070640A (zh) * 2009-11-24 2011-05-25 上海药明康德新药开发有限公司 一种1,7-二氮杂螺[4,5]壬烷及其衍生物的合成方法
BR112012030004A2 (pt) 2010-05-27 2016-08-02 Targacept Inc antagonistas não competitivos de receptor nicotínico
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
CN102516146B (zh) * 2011-11-24 2013-10-02 爱斯特（成都）生物制药有限公司 5位为氮的四元氮杂螺环衍生物及其制备方法和用途
GB201416351D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
RU2635105C1 (ru) * 2016-07-15 2017-11-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный университет" Способ получения 4-арил-2,7,9-триазаспиро[4.5]декан-6,8,10-трионов
CN109937204B (zh) * 2016-08-01 2022-11-25 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
BR112022024729A2 (pt) 2020-06-05 2023-02-28 Kinnate Biopharma Inc Inibidores de quinases do receptor do fator de crescimento de fibroblastos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282947A (en) * 1962-05-17 1966-11-01 Geschickter Fund Med Res Unsymmetrically substituted 3, 9-diazaspiro(5, 5)undecane compounds
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
DK0687268T3 (da) * 1993-03-04 1998-10-12 Pfizer Spiroazacykliske derivater som substans P-antagonister
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
WO1997001556A1 (en) * 1995-06-29 1997-01-16 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5733912A (en) * 1997-02-19 1998-03-31 Abbott Laboratories 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
DK0970957T3 (da) * 1998-06-12 2001-12-03 Hoffmann La Roche Diaza-spiro[3.5]nonan-derivativer
WO2001030780A2 (en) * 1999-10-27 2001-05-03 Cor Therapeutics, Inc. Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
NZ521346A (en) * 2000-04-10 2004-07-30 Pfizer Prod Inc Benzoamide piperidine containing compounds and related compounds
NZ566367A (en) * 2002-07-05 2009-04-30 Targacept Inc N-Aryl diazaspiracyclic compounds capable of affecting nicotinic cholinergic receptors and methods of preparation and use thereof

Also Published As

Publication number Publication date
RU2007110020A (ru) 2008-09-27
CN101022801A (zh) 2007-08-22
JP2008510711A (ja) 2008-04-10
KR20070043008A (ko) 2007-04-24
RU2387647C9 (ru) 2011-05-27
CA2575461A1 (en) 2006-03-02
US20060058328A1 (en) 2006-03-16
MX2007002045A (es) 2007-03-29
ZA200701193B (en) 2009-09-30
WO2006023630A3 (en) 2006-05-04
IL180929A0 (en) 2007-07-24
AU2005277410A1 (en) 2006-03-02
BRPI0514509A (pt) 2008-06-10
EP1784184A2 (en) 2007-05-16
NZ552792A (en) 2009-12-24
RU2387647C2 (ru) 2010-04-27
WO2006023630A2 (en) 2006-03-02
UA92327C2 (ru) 2010-10-25
AU2005277410B2 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
NO20070979L (no) Anvendelse av N-aryldiazaspirasykliske forbindelser i behandling av avhengighet
DK1519939T3 (da) N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
TW200606147A (en) Indolyl derivatives as liver-X-receptor modulators
JP2011500506A5 (no)
WO2002083109A1 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
AU2002244860A1 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV
MX2009012558A (es) Combinaciones de farmacos para el tratamiento de distrofia muscular de duchenne.
IN2015DN01132A (no)
JP2007519649A5 (no)
CY1109370T1 (el) Παραγωγα οξαδιαζολονης ως ppar δελτα αγωνιστες
JP2014528901A5 (no)
JP2019515908A5 (no)
NO20050569L (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
TW200604193A (en) Substituted oxazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
JP2019520344A5 (no)
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
SI1634595T1 (sl) N-fenilbenzamidni derivati kot zdravila za zdravljenje kronične obstruktivne pljučne bolezni (KOPB)
US20230250054A1 (en) Selective histone deacetylase 6 inhibitors
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
CN113544121A (zh) 具有β2受体激动及M受体拮抗活性的杂环衍生物及其医药用途
MX2008015324A (es) Derivados de pirrolidina utiles como inhibidores de bace.
MY137679A (en) 2-ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders
JP2010536778A5 (no)
WO2009038107A1 (ja) ２型糖尿病治療用の組合せ医薬
RU2006137503A (ru) Способ лечения диэнцефально-катаболического синдрома

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application